Select Publications
Book Chapters
2020, 'Clinical Management', in In The International Academy of Cytology Yokohama System for Reporting Breast Fine Needle Aspiration Biopsy Cytopathology Atlas
,2020, 'The International Academy of Cytology Yokohama System for Reporting Breast Fine Needle Aspiration Biopsy Cytopathology: Introduction and Overview', in The International Academy of Cytology Yokohama System for Reporting Breast Fine Needle Aspiration Biopsy Cytopathology, pp. 1 - 9, http://dx.doi.org/10.1007/978-3-030-26883-1_1
,2019, 'Breast Cancer: The facts', in Breast Cancer: The Facts, Oxford University Press
,2015, 'Adjuvant chemotherapy in breast cancer', in Breast disease: Comprehensive management, pp. 335 - 351, http://dx.doi.org/10.1007/978-1-4939-1145-5_23
,Journal articles
2024, 'Characterisation and reproducibility of the HumanMethylationEPIC v2.0 BeadChip for DNA methylation profiling', BMC Genomics, 25, http://dx.doi.org/10.1186/s12864-024-10027-5
,2024, 'The androgen receptor interacts with GATA3 to transcriptionally regulate a luminal epithelial cell phenotype in breast cancer', Genome Biology, 25, http://dx.doi.org/10.1186/s13059-023-03161-y
,2024, 'Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial', The Lancet Oncology, 25, pp. 317 - 325, http://dx.doi.org/10.1016/S1470-2045(24)00004-4
,2024, 'The potential of epigenetic therapy to target the 3D epigenome in endocrine-resistant breast cancer', Nature Structural and Molecular Biology, 31, pp. 498 - 512, http://dx.doi.org/10.1038/s41594-023-01181-7
,2024, 'Selective CDK7 inhibition suppresses cell cycle progression and MYC signaling while enhancing apoptosis in therapy-resistant estrogen receptor positive breast cancer.', Clin Cancer Res, http://dx.doi.org/10.1158/1078-0432.CCR-23-2975
,2024, 'Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer', Clinical Cancer Research, 30, pp. 754 - 766, http://dx.doi.org/10.1158/1078-0432.CCR-23-1796
,2024, 'Interleukin-3 production by basal-like breast cancer cells is associated with poor prognosis', Growth Factors, http://dx.doi.org/10.1080/08977194.2023.2297693
,2024, 'Tumor Biomechanics Alters Metastatic Dissemination of Triple Negative Breast Cancer via Rewiring Fatty Acid Metabolism', Advanced Science, http://dx.doi.org/10.1002/advs.202307963
,2023, 'Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel', Drug Safety, 46, pp. 927 - 949, http://dx.doi.org/10.1007/s40264-023-01328-x
,2023, 'Oral vinorelbine to treat women with ectopic pregnancy: a phase 1 clinical safety and tolerability study', Fertility and Sterility, 120, pp. 695 - 696, http://dx.doi.org/10.1016/j.fertnstert.2023.05.161
,2023, 'Antibody–Drug Conjugates: Ushering in a New Era of Cancer Therapy', Pharmaceutics, 15, http://dx.doi.org/10.3390/pharmaceutics15082017
,2023, 'Exploratory biomarker analysis of acelERA breast cancer (BC): Phase II study of giredestrant vs. physician’s choice of endocrine therapy (PCET) for previously treated, estrogen receptor-positive, HER2-negative advanced BC (ER+, HER2– aBC).', Journal of Clinical Oncology, 41, pp. 1069 - 1069, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.1069
,2023, 'Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER-positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor', Cancer Communications, 43, pp. 720 - 725, http://dx.doi.org/10.1002/cac2.12425
,2023, 'Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial', The Lancet, 401, pp. 1773 - 1785, http://dx.doi.org/10.1016/S0140-6736(23)00725-0
,2023, 'Monitoring AKT activity and targeting in live tissue and disease contexts using a real-time Akt-FRET biosensor mouse', Science Advances, 9, http://dx.doi.org/10.1126/sciadv.adf9063
,2023, 'Abstract GS2-01: GS2-01 Trastuzumab deruxtecan vs physician’s choice in patients with HER2+ unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine: primary results of the randomized, phase 3 study DESTINY-Breast02', Cancer Research, 83, http://dx.doi.org/10.1158/1538-7445.sabcs22-gs2-01
,2023, 'Abstract OT1-02-02: A phase 1/2 study to evaluate the safety and efficacy of EP0062, an oral Selective Androgen Receptor Modulator (SARM), for the treatment of AR+/HER2-/ER+ advanced breast cancer', Cancer Research, 83, http://dx.doi.org/10.1158/1538-7445.sabcs22-ot1-02-02
,2023, 'Abstract OT2-01-10: WinPro: A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early-stage hormone receptor-positive breast cancer', Cancer Research, 83, http://dx.doi.org/10.1158/1538-7445.sabcs22-ot2-01-10
,2023, 'Abstract OT2-10-05: HER2Pro: A Phase 1b dose de-escalation study of high dose prochlorperazine added to paclitaxel, trastuzumab and pertuzumab in patients with previously untreated HER2-positive metastatic breast cancer', Cancer Research, 83, http://dx.doi.org/10.1158/1538-7445.sabcs22-ot2-10-05
,2023, 'Abstract PD13-04: PD13-04 Exploratory subgroup and biomarker analyses of acelERA Breast Cancer: Phase II study of giredestrant (GDC-9545) vs physician’s choice of endocrine therapy for previously treated, estrogen receptor+, HER2– advanced breast cancer', Cancer Research, 83, http://dx.doi.org/10.1158/1538-7445.sabcs22-pd13-04
,2023, 'Abstract PD13-12: PD13-12 Imlunestrant, an oral selective estrogen receptor degrader, in combination with abemaciclib with or without an aromatase inhibitor, in estrogen receptor-positive advanced breast cancer: Results from the phase 1a/b EMBER study', Cancer Research, 83, http://dx.doi.org/10.1158/1538-7445.sabcs22-pd13-12
,2023, 'Abstract PD9-01: Stromal mediators of lymphocyte exclusion and dysfunction in triple negative breast cancer', Cancer Research, 83, http://dx.doi.org/10.1158/1538-7445.sabcs22-pd9-01
,2023, 'CDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective', Frontiers in Cell and Developmental Biology, 11, http://dx.doi.org/10.3389/fcell.2023.1148792
,2023, '383MO Imlunestrant with or without everolimus or alpelisib, in ER+, HER2- advanced breast cancer (aBC): Results from the phase Ia/b EMBER study', Annals of Oncology, 34, pp. S338 - S339, http://dx.doi.org/10.1016/j.annonc.2023.09.560
,2023, '413P Characteristics of patients (pts) with previously treated, oestrogen receptor-positive, HER2-negative advanced breast cancer (ER+, HER2– aBC) who had rapid progression (RP) in acelERA BC', Annals of Oncology, 34, pp. S356 - S357, http://dx.doi.org/10.1016/j.annonc.2023.09.590
,2022, 'Real-World Outcomes of Ribociclib and Aromatase Inhibitor Use in First Line Hormone Receptor Positive, HER2-Negative Metastatic Breast Cancer', Clinical Breast Cancer, 22, pp. 792 - 800, http://dx.doi.org/10.1016/j.clbc.2022.08.011
,2022, 'Temporal profiling of the breast tumour microenvironment reveals collagen XII as a driver of metastasis', Nature Communications, 13, http://dx.doi.org/10.1038/s41467-022-32255-7
,2022, 'An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancer', Breast Cancer Research and Treatment, 195, pp. 275 - 287, http://dx.doi.org/10.1007/s10549-022-06690-5
,2022, 'Diagnostic value of 68Ga-DOTATATE PET-CT imaging for staging of ER+/PR+ HER2- breast cancer patients with metastatic disease: Comparison with conventional imaging with bone scan, diagnostic CT and 18F-FDG PET-CT in a prospective pilot trial', Journal of Medical Imaging and Radiation Oncology, 66, pp. 731 - 737, http://dx.doi.org/10.1111/1754-9485.13342
,2022, '64Cu-SAR-Bombesin PET-CT Imaging in the Staging of Estrogen/Progesterone Receptor Positive, HER2 Negative Metastatic Breast Cancer Patients: Safety, Dosimetry and Feasibility in a Phase I Trial', Pharmaceuticals, 15, http://dx.doi.org/10.3390/ph15070772
,2022, 'Computational Screening of Anti-Cancer Drugs Identifies a New BRCA Independent Gene Expression Signature to Predict Breast Cancer Sensitivity to Cisplatin', Cancers, 14, http://dx.doi.org/10.3390/cancers14102404
,2022, 'Paracrine IL-6 Signaling Confers Proliferation between Heterogeneous Inflammatory Breast Cancer Sub-Clones', Cancers, 14, http://dx.doi.org/10.3390/cancers14092292
,2022, 'A new sophistication for breast cancer PDXs', Nature Cancer, 3, pp. 138 - 140, http://dx.doi.org/10.1038/s43018-021-00328-z
,2022, 'Effects of Endocrine Therapy on Cognitive Function in Patients with Breast Cancer: A Comprehensive Review', Cancers, 14, http://dx.doi.org/10.3390/cancers14040920
,2022, 'Epigenetic Therapies and Biomarkers in Breast Cancer', Cancers, 14, http://dx.doi.org/10.3390/cancers14030474
,2022, 'Impact of the EndoPredict genomic assay on treatment decisions for oestrogen receptor-positive early breast cancer patients: benefits of physician selective testing', Breast Cancer Research and Treatment, 191, pp. 501 - 511, http://dx.doi.org/10.1007/s10549-021-06456-5
,2022, 'Oral Selective Estrogen Receptor Degraders (SERDs) in Breast Cancer: Advances, Challenges, and Current Status', Drug Design, Development and Therapy, 16, pp. 2933 - 2948, http://dx.doi.org/10.2147/DDDT.S380925
,2022, '211MO Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase II, randomised, open-label acelERA BC study', Annals of Oncology, 33, pp. S633 - S634, http://dx.doi.org/10.1016/j.annonc.2022.07.250
,2021, 'Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study', Annals of Oncology, 32, pp. 1571 - 1581, http://dx.doi.org/10.1016/j.annonc.2021.09.015
,2021, 'Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer', Nature Communications, 12, http://dx.doi.org/10.1038/s41467-021-25422-9
,2021, 'Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis', Genome Medicine, 13, http://dx.doi.org/10.1186/s13073-021-00885-z
,2021, 'Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models', Breast Cancer Research, 23, http://dx.doi.org/10.1186/s13058-021-01461-4
,2021, 'Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer (Nature Communications, (2021), 12, 1, (5112), 10.1038/s41467-021-25422-9)', Nature Communications, 12, http://dx.doi.org/10.1038/s41467-021-25901-z
,2021, 'Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition', npj Breast Cancer, 7, http://dx.doi.org/10.1038/s41523-021-00312-x
,2021, 'MDM2 as a Rational Target for Intervention in CDK4/6 Inhibitor Resistant, Hormone Receptor Positive Breast Cancer', Frontiers in Oncology, 11, http://dx.doi.org/10.3389/fonc.2021.777867
,2021, 'Heart failure therapies for the prevention of her2-monoclonal antibody-mediated cardiotoxicity: A systematic review and meta-analysis of randomized trials', Cancers, 13, pp. 5527, http://dx.doi.org/10.3390/cancers13215527
,